FDA approves GSK asthma inhaler Arnuity Ellipta
- Arnuity Ellipta (fluticasone furoate) is a once-daily inhaler for asthma maintenance or prophylactic asthma therapy in patients aged 12 and up. It is not meant to treat acute bronchospasm.
- This is the first treatment from GSK’s new portfolio to be approved by the FDA.
- GSK is using Ellipta, a dry powder, for development of various respiratory therapies.
The clinical data that led to FDA approval of Arnuity Ellipta included more than 3,600 patients.
Although there are numerous asthma treatments on the market, more than half of the 26 million people in the US who have asthma do not have effective methods to control or maintain the disease. In fact, many people with asthma continue to rely on relief medication. The goal of this treatment is to reduce that trend.